Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

The Liposome Co. Inc.

(LIPO)

Pandya rated LIPO a "long term buy." Its

Read the full 132 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE